ITBMed is a biopharmaceutical company developing specific immunomodulatory biologics for transplantation, autoimmunity, neurodegenerative diseases, and gene therapy. The lead candidate drug siplizumab is a monoclonal antibody in clinical development,..
Relevance: 34.1652